ArticleBMC women's health2010
Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy.
Article in BMC women's health, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.BMC medical informatics and decision making · 2019Pooled it
- Coping Self-Efficacy and Its Relationship with Psychological Morbidity after Genetic Test Result Disclosure: Results from Cancer-UnaffectedInternational journal of environmental research and public health · 2023Trial
- Personalized Decision-Making in Risk-Reducing Surgery of the Ovaries.JAMA network open · 2026Article
- Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers ofWorld journal of oncology · 2026Review
- Intimate partners' participation in risk-management decision making by women at elevated risk of breast cancer: An exploratory qualitative study.SSM. Qualitative research in health · 2025Article
- Racial differences in prevention decision making among U.S. women at high risk of breast cancer: A qualitative study.PloS one · 2023Article
- Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study.Hereditary cancer in clinical practice · 2022Article
- Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.JCO oncology practice · 2022Review
- Surgical decision making in premenopausalJournal of medical genetics · 2022Observational
- Decision-making for Risk-reducing Salpingo-oophorectomy (RRSO) in Southeast Asian BRCA Mutation Carriers With Breast Cancer: A Qualitative Study.International journal of behavioral medicine · 2022Article
- Population genomic screening: Ethical considerations to guide age at implementation.Frontiers in genetics · 2022Review
- The needs of Southeast Asian BRCA mutation carriers considering risk-reducing salpingo-oophorectomy: a qualitative study.Familial cancer · 2022Article
- Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test.Public health genomics · 2020Article
- Decision making for breast cancer prevention among women at elevated risk.Breast cancer research : BCR · 2017Review
- Exploration of Male Attitudes on Partnerships and Sexuality with Female BRCA1/2 Mutation Carriers.Journal of genetic counseling · 2016Article
- Living With Genetic Vulnerability: a Life Course Perspective.Journal of genetic counseling · 2016Article
- Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.Familial cancer · 2015Article
- A pilot study of BRCA mutation carriers' knowledge about the clinical impact of prophylactic-oophorectomy and views on fertility consultation: a single-center pilot study.Journal of genetic counseling · 2015Article
- Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation.Journal of genetic counseling · 2014Article
- Catalysts to withdrawal from familial ovarian cancer screening for surgery and reactions to discontinued screening: a qualitative study.Familial cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWomen who are notified they carry a BRCA1/2 mutation are presented with surgical options to reduce their risk of breast and ovarian cancer, including risk-reducing mastectomy (RRM) and risk-reducing oophorectomy (RRO). Growing evidence suggests that a sub-group of women do not make decisions about RRM and RRO immediately following genetic testing, but rather, consider these decisions years later. Women's perspectives on the timing of these decisions are not well understood. Accordingly, the purpose of this research was to describe how women construct the 'right time' to consider decisions about RRM and RRO.
methodsIn-depth interviews were conducted with 22 BRCA1/2 carrier women and analyzed using qualitative, constant comparative methods.
resultsThe time that lapsed between receipt of genetic test results and receipt of RRM or RRO ranged from three months to nine years. The findings highlighted the importance of considering decisions about RRM and RRO one at a time. The women constructed the 'right time' to consider these decisions to be when: (1) decisions fit into their lives, (2) they had enough time to think about decisions, (3) they were ready emotionally to deal with the decisions and the consequences, (4) all the issues and conflicts were sorted out, (5) there were better options available, and (6) the health care system was ready for them.
conclusionsThese findings offer novel insights relevant to health care professionals who provide decision support to women considering RRM and RRO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.